Vis enkel innførsel

dc.contributor.authorSelnæs, Kirsten Margrete
dc.contributor.authorKrüger-Stokke, Brage
dc.contributor.authorElschot, Mattijs
dc.contributor.authorWilloch, Frode
dc.contributor.authorStørkersen, Øystein
dc.contributor.authorSandsmark, Elise
dc.contributor.authorMoestue, Siver Andreas
dc.contributor.authorTessem, May-Britt
dc.contributor.authorHalvorsen, Dag
dc.contributor.authorKjøbli, Eirik
dc.contributor.authorAngelsen, Anders
dc.contributor.authorLangørgen, Sverre
dc.contributor.authorBertilsson, Helena
dc.contributor.authorBathen, Tone Frost
dc.date.accessioned2019-08-29T13:21:33Z
dc.date.available2019-08-29T13:21:33Z
dc.date.created2018-07-09T13:14:56Z
dc.date.issued2018
dc.identifier.citationEuropean Radiology. 2018, 1-9.nb_NO
dc.identifier.issn0938-7994
dc.identifier.urihttp://hdl.handle.net/11250/2611677
dc.description.abstractObjective To investigate the diagnostic potential of simultaneous 18F-fluciclovine PET/MRI for pelvic lymph node (LN) staging in patients with high-risk prostate cancer. Methods High-risk prostate cancer patients (n=28) underwent simultaneous 18F-fluciclovine PET/MRI prior to surgery. LNs were removed according to a predefined template of eight regions. PET and MR images were evaluated for presence of LN metastases according to these regions. Sensitivity/specificity for detection of LN metastases were calculated on patient and region basis. Sizes of LN metastases in regions with positive and negative imaging findings were compared with linear mixed models. Clinical parameters of PET-positive and -negative stage N1 patients were compared with the Mann-Whitney U test. Results Patient- and region-based sensitivity/specificity for detection of pelvic LN metastases was 40 %/87.5 % and 35 %/95.7 %, respectively, for MRI and 40 %/100 % and 30 %/100 %, respectively, for PET. LN metastases in true-positive regions were significantly larger than metastases in false-negative regions. PET-positive stage N1 patients had higher metastatic burden than PET-negative N1 patients. Conclusion Simultaneous 18F-fluciclovine PET/MRI provides high specificity but low sensitivity for detection of LN metastases in high-risk prostate cancer patients. 18F-Fluciclovine PET/MRI scan positive for LN metastases indicates higher metastatic burden than negative scannb_NO
dc.language.isoengnb_NO
dc.publisherSpringer Verlagnb_NO
dc.title18F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patientsnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumber1-9nb_NO
dc.source.journalEuropean Radiologynb_NO
dc.identifier.doi10.1007/s00330-017-5213-1
dc.identifier.cristin1596372
dc.relation.projectNorges forskningsråd: 239940nb_NO
dc.description.localcodeThis article will not be available due to copyright restrictions © 2018 by Springer Verlagnb_NO
cristin.unitcode194,65,25,0
cristin.unitcode194,65,15,0
cristin.unitnameInstitutt for sirkulasjon og bildediagnostikk
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel